BioCentury | Nov 20, 2020
Regulation

WHO counters FDA as it recommends against Veklury for COVID-19

...or ECMO.The EUA is based on data from NIH’s ACTT-2 trial, which showed the oral JAK-1/JAK-2...
...INCB28050 (Former compound #), baricitinib (Generic), Olumiant (Other) Gilead Sciences Inc. Eli Lilly and Co. Incyte Corp. Janus kinase-1 (JAK-1) Janus kinase-2 (JAK-2) COVID-19 cov19count chs2020 cov19count...
BioCentury | Nov 14, 2020
Emerging Company Profile

Metagenomi hunts for new gene editing systems with $65M series A

...with “low or zero off-target activity profiles.” CBO Jak...
BioCentury | Nov 11, 2020
Product Development

Arena sees clear path to atopic dermatitis Phase III for etrasimod despite data that shed $1B in value

...show a greater benefit to compete with JAK-1...
...may have an advantage is on safety. JAK-1...
...Phase II/III trial for Crohn’s disease.TARGETSJAK-1 – Janus kinase-1S1PR1...
BioCentury | Nov 3, 2020
Product Development

Nov. 2 Quick Takes: EMA reviewing filgotinib and DBV’s peanut allergy therapy; plus Royalty Pharma-CF Foundation, CARSgen, Karyopharm, Aurinia, Regeneron and Astellas

...reviewing its MAA for Jyseleca filgotinib to treat ulcerative colitis. The partners are seeking the JAK...
...Food and Drug Administration (FDA) Gilead Sciences Inc. Galapagos N.V. Karyopharm Therapeutics Inc. Aurinia Pharmaceuticals Inc. Regeneron Pharmaceuticals Inc. Astellas Pharma Inc. Janus kinase (JAK) Exportin...
BioCentury | Oct 29, 2020
Product Development

Gilead leaning on cancer deals for growth as filgotinib’s future hangs in the balance

...in Europe and Japan, and Gilead plans to submit an MAA to EMA for the JAK...
BioCentury | Oct 22, 2020
Product Development

Data Byte: AbbVie’s oral JAK takes the lead in coming competition for Dupixent in atopic dermatitis

...efficacy, compared with three other Phase III programs and the marketed therapy Dupixent dupilumab.The oral JAK-1...
...CHRONOS trials tested the therapies in combination with topical steroids.Olumiant baracitinib is a JAK-1 and JAK-2...
...plc (LSE:AZN; NYSE:AZN).TARGETSIL-4R (IL-4RA, CD124) – Interleukin-4 (IL-4) receptorIL-13 – Interleukin 13JAK-1 – Janus kinase-1JAK-2 – Janus kinase-2 Stephen...
BioCentury | Oct 19, 2020
Finance

How Nimbus’ focus on internal pipeline could point to long-awaited exit

...matters for TYK2, one of the four JAK...
...therapy targets the catalytic domain of one JAK...
...disease without the adverse effects seen in pan-JAK...
BioCentury | Oct 13, 2020
Product Development

Gilead’s Jyseleca has a leg up over BMS’s Zeposia in biologic-experienced UC patients

...oral therapy marketed for UC, but the JAK...
...significance vs. placebo.Jyseleca is more selective for JAK-1...
...Hansen Jyseleca, filgotinib (GLPG0634, GS-6034) Gilead Sciences Inc. Galapagos N.V. Janus kinase-1 (JAK-1) Sphingosine...
BioCentury | Sep 29, 2020
Financial News

Sept. 28 Quick Takes: Biogen gains $1.4B on aducanumab update; plus Zai, XtalPi, InventisBio, Galecto, Innovent, Galapagos-Gilead, Biocytogen and ACT Accelerator

...in Japan to treat rheumatoid arthritis. The JAK...
BioCentury | Sep 19, 2020
Regulation

Data Bytes: CHMP’s September recommendations

...first JAK1 and JAK2 inhibitor on the market for the indication.  TARGETSJAK1 – Janus kinase-1JAK2 – Janus kinase-2 Virginia...
Items per page:
1 - 10 of 867